Is Zimmer Biomet Holdings (ZBH) Undervalued After Raising Earnings Guidance?

Zimmer Biomet Holdings (ZBH) recently reaffirmed its 1% to 3% revenue growth outlook while lifting earnings guidance, highlighting early benefits from its commercial overhaul and increased focus on robotics solutions.

See our latest analysis for Zimmer Biomet Holdings.

Zimmer Biomet Holdings’ recent guidance update comes as the stock shows modest positive momentum, with a 7.76% 1 month share price return and a 3.40% 7 day share price return, set against a 5 year total shareholder return that has declined 39.98%.

If Zimmer Biomet’s robotics push has your attention, it can be helpful to see what else is on the move in related areas, including 39 healthcare AI stocks.

With Zimmer Biomet Holdings trading near US$90.96, an implied discount to both analyst targets and some intrinsic value estimates hints at potential upside. However, recent share underperformance raises a key question: is this a genuine opportunity, or is the market already pricing in future growth?

Price-to-Earnings of 23.1x: Is it justified?

Zimmer Biomet Holdings currently trades on a P/E of 23.1x, which screens as good value relative to both peers and the broader US Medical Equipment industry based on Simply Wall St’s checks.

The P/E multiple compares the company’s share price to its earnings per share, so it effectively shows how much investors are paying for each dollar of Zimmer Biomet’s profits. For a medical technology company with global scale, established products and forecast earnings growth, this metric is a common way to benchmark expectations.

According to the statements, Zimmer Biomet is considered good value at 23.1x not only against the US Medical Equipment industry average of 25x, but also against a peer average of 33.4x. The P/E is also below an estimated fair P/E of 25.6x. This is the level the market could move towards if sentiment and fundamentals align more closely with that fair ratio assessment.

Explore the SWS fair ratio for Zimmer Biomet Holdings

Result: Price-to-Earnings of 23.1x (UNDERVALUED)

However, Zimmer Biomet’s recent share underperformance over 3 and 5 years, along with the long investment cycles in orthopedic robotics, could both challenge any quick rerating story.

Find out about the key risks to this Zimmer Biomet Holdings narrative.

Another View: Zimmer Biomet Holdings Through a Cash Flow Lens

While the 23.1x P/E suggests Zimmer Biomet Holdings is on the cheaper side compared to peers, the SWS DCF model paints an even stronger value gap. With the stock at $90.96 and a future cash flow value estimate of $209.57, the model points to a very wide margin between price and implied worth.

If one method flags modest upside and another signals a much deeper discount, which picture should carry more weight for you as an investor: the earnings snapshot or the long term cash flow view?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Zimmer Biomet Holdings for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 43 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If Zimmer Biomet Holdings’ mix of potential risks and rewards feels finely balanced, it may be worth taking time now to inspect the details yourself and decide where you stand, starting with the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Zimmer Biomet Holdings?

If Zimmer Biomet Holdings has sharpened your focus, now is a good moment to widen the lens and uncover other opportunities using the Simply Wall St screener.

• Target potential upside by reviewing companies that currently screen as 43 high quality undervalued stocks before the wider market catches on.
• Strengthen your focus on resilience by filtering for 67 resilient stocks with low risk scores that aim to limit unpleasant surprises when conditions change.
• Spot potential future leaders early by scanning the screener containing 19 high quality undiscovered gems that may not be on everyone’s radar yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com